Usefulness of Selegiline as an Aid to Quit Smoking - 1
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00129311|
Recruitment Status : Completed
First Posted : August 11, 2005
Results First Posted : July 16, 2014
Last Update Posted : March 31, 2015
|Condition or disease||Intervention/treatment||Phase|
|Tobacco Use Cessation||Drug: Selegiline Drug: Placebo||Phase 2|
Despite the availability of nicotine replacement therapies and sustained-relapse bupropion for the treatment of nicotine dependence, there is still a significant proportion of cigarette smokers who are unable to quit smoking. Therefore, new and effective pharmacotherapies for smoking cessation are needed. The primary aim of this study is to determine the safety and efficacy of selegiline as an aid to smoking cessation.
In this study, 200 nicotine-dependent cigarette smokers will participate in an 8-week, double-blind, placebo-controlled trial and then will be followed over 4 years. Participants will be randomly assigned to receive either selegiline or placebo. Selegiline doses of 5 mg will be taken once a day during the first week. This will be increased to 5 mg twice daily for the remaining 7 weeks. The target smoking "quit date" will be Day 15. All smokers will receive brief weekly manualized smoking cessation counseling from the Mayo Clinic's "Smoke Free and Livin' It" program. The primary smoking cessation outcome measure will be 7-day point prevalence smoking abstinence at the 6-month follow-up. Secondary cessation outcome measures will include continuous smoking abstinence during the last four weeks of the trial (Days 29-56) and 7-day point prevalence abstinence at the end of the 8-week trial (Days 49-56).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||101 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Usefulness of Selegiline for Smoking Cessation|
|Study Start Date :||July 2004|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
Other Name: L-deprenyl; Eldepryl®
Placebo Comparator: 2
- 7 Day Point Prevalence of Cigarette Abstinence [ Time Frame: 6-month follow up ]
- 7 Day Point Prevalence of Cigarette Abstinence [ Time Frame: Week 8 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00129311
|United States, Connecticut|
|New Haven, Connecticut, United States, 06511|
|Principal Investigator:||Tony P George, M.D.||Yale University|
|Principal Investigator:||Marc N Potenza, M.D., Ph.D.||Yale University|